New stem cell particle injection could soothe severe eczema

NCT ID NCT06055361

Recruiting now Disease control Sponsor: Brexogen Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests an experimental injection called BxC-I17e, made from stem cell particles, in 45 adults with moderate to severe eczema (atopic dermatitis) who haven't responded well to standard creams. The main goal is to check safety and tolerability, with a small look at whether it helps symptoms. It's a first step to see if this approach is worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BxC-I17e (a cell-based injection made from stem cell particles)
What this could lead to: If safe and effective, this could point toward a new treatment option for moderate to severe eczema that is easier to manage.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The treatment may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Arkansas Research Trials
RECRUITING

North Little Rock, Arkansas, 72117, United States
DermDox Centers for Dermatology
RECRUITING

Camp Hill, Pennsylvania, 17011, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.